Clinical Trial Update: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes [Phase 2]

View source ↗

Summary

This trial update reports on a Phase 2 study of ISIS-GCGRRx in Type 2 Diabetes, focusing on safety, tolerability, and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ISIS-GCGRRx

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED